BiomX (PHGE) Stock Price, News & Analysis

Company Overview

BiomX Inc. is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis. Preclinical studies have demonstrated the ability of BiomX’s phage preparations to reduce targeted bacterial populations implicated in inflammation and disease progression. Advanced product characterization and manufacturing processes support both oral and topical delivery formats, positioning BiomX to advance multiple candidates through regulatory pathways.

Founded in 2016 as a spin-out from MIGAL – Galilee Research Institute, BiomX is headquartered in Rehovot, Israel, with a U.S. presence in Cambridge, Massachusetts. The company conducts clinical trials across North America and Europe, collaborating with academic medical centers and contract research organizations. Since its initial public listing on the NYSE American exchange under the ticker PHGE, BiomX has expanded its leadership team to include executives with deep expertise in phage biology, clinical development and biomanufacturing. The company’s research and development efforts are overseen by CEO Eliora Ron, who guides strategic initiatives to translate microbiome science into targeted, next-generation therapies.

Key Stats

• Today's Range: $0.19 to $0.20
• 50-Day Range: $0.20 to $1.62
• 52-Week Range: $0.19 to $13.70
• Volume: 343,582 shs
• Average Volume: 4.06 million shs
• Market Capitalization: $2.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.00
• Consensus Rating: Hold

BiomX Stock Analysis - MarketRank™

BiomX scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

BiomX has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

BiomX has a consensus price target of $26.00, representing about 13,226.5% upside from its current price of $0.20.

Amount of Analyst Coverage

BiomX has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for BiomX are expected to decrease in the coming year, from ($5.85) to ($6.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BiomX is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BiomX is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.89% of the float of BiomX has been sold short.

Short Interest Ratio / Days to Cover

BiomX has a short interest ratio ("days to cover") of 0.48, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BiomX has recently decreased by 1.96%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BiomX does not currently pay a dividend.

Dividend Growth

BiomX does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 3 people have searched for PHGE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BiomX insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.18% of the stock of BiomX is held by insiders.

Percentage Held by Institutions

40.57% of the stock of BiomX is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/20/2026
• Today: 7/20/2026
• Next Earnings (Estimated): 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:PHGE
• Previous Symbol: NYSEMKT:PHGE
• CIK: 1739174
• Web: www.biomx.com
• Phone: 972-7-2394-2377
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BiomX: $26.00
• High Price Target: $26.00
• Low Price Target: $26.00
• Potential Upside/Downside: +12,900.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -89.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.24
• Quick Ratio: 1.24

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($12.50) per share
• Price / Book: -0.02

Miscellaneous

• Outstanding Shares: 11,800,000
• Free Float: 11,776,000
• Market Cap: $2.36 million
• Optionable: N/A
• Beta: 1.30